Effect of Infliximab in Hepatitis-C Genotype 1 Naïve Patients With High TNF-Alpha on the Efficacy of Pegylated Interferon Alfa-2b/Ribavirin Therapy.

Trial Profile

Effect of Infliximab in Hepatitis-C Genotype 1 Naïve Patients With High TNF-Alpha on the Efficacy of Pegylated Interferon Alfa-2b/Ribavirin Therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Infliximab (Primary) ; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Nov 2012 Primary endpoint 'Sustained-virological-response' has not been met.
    • 28 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Apr 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top